Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)
Eli Lilly and Company
Eric F Morand; Edward M Vital; Michelle Petri; Ronald van Vollenhoven; Daniel J Wallace; Marta Mosca; Richard A Furie; Maria E Silk; Christina L Dickson; Gabriella Meszaros; Bochao Jia; Brenda Crowe; Inmaculada de la Torre; Thomas Dörner